A recent study suggests that individuals who discontinue new GLP-1 drugs like Wegovy and Mounjaro may regain reduced body mass much more quickly than those who end conventional diet and exercise regimens.
Published data in a leading health publication shows that while overweight people frequently drop substantial amounts of their total mass while on the medication, the mass returns at an average rate of 0.8 kg per month once they quit.
"Users purchasing these drugs must be cognizant of the danger of fast rebound weight gain when the treatment ends," warns lead investigator Dr. Susan Jebb.
Such speed of recovery suggests a reversion to starting mass in about one and a half years.
Analyzing Treatments
The research, which reviewed dozens of studies involving over 9,000 of patients, compared the outcomes of GLP-1 agonists with older methods.
Researchers emphasize that people who shed pounds through dieting typically have a more gradual creep back—perhaps 0.1 kg a month—once they finish.
The Reason for the Quick Rebound
Doctors suggest the mechanism of the injections is key to understanding the accelerated weight return.
GLP-1 drugs mimic a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Artificially providing GLP-1 concentrations several times higher than normal might result in the body to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its effects," said Dr. Adam Collins, a dietetics researcher.
"Discontinuation of this GLP-1 'fix' means appetite is unsuppressed, making binge eating far more likely."
A Lifelong Issue?
Medical guidelines suggest the injections for people with weight-linked health risks, alongside prescribed diet and exercise modifications.
Many experts argue that, given the high risk of weight regain, the treatment should be considered ongoing.
This opinion is supported by drug manufacturers, who state that the results "underscore the long-term nature of excess weight," comparing it to managing conditions like hypertension.
Patient Experiences
Users who have discontinued the medication report a intense resurgence of appetite.
"It was like a switch activating and I was suddenly ravenous," said an individual.
The struggle is compounded if users have not adopted lasting dietary or behavioural modifications during therapy.
Growing Use
Survey data show that a significant number of people in the UK have used weight-loss jabs in the last 12 months, with interest being substantial.
- Use is more common among women compared to males.
- The middle-aged age group shows the highest level of interest.
- Many access the medications through private healthcare rather than public health services.
Finally, experts caution that while these medications are potent tools for shedding pounds, they are not a magic solution and lasting health benefits likely depends on integrated behavioural support.
